JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the year and the quarter ended December 31, 2016.
“While we continue to manage through a turbulent and constantly evolving industry, we are committed to execute against our strategy with more diversified revenue sources and profit streams, all backed by strong product development engines in both generics and specialty.”
| FY 2016 | Q4 2016 | ||||||
| Revenues | $21.9 billion | $6.5 billion | |||||
| Cash flow from operations | $5.2 billion | $1.4 billion | |||||
| GAAP EPS | $0.07 | ($1.10) | |||||
| Non-GAAP EPS | $5.14 | $1.38 | |||||
| Teva reaffirms its 2017 full year non-GAAP guidance; | |||||||
| including revenues of $23.8 - 24.5 billion, and | |||||||
| non-GAAP EPS of $4.90 - 5.30 | |||||||
“2016 was a transitional year for Teva – one that included significant achievements, as well as challenges,” stated Dr. Yitzhak Peterburg, Interim President and CEO of Teva. “While we continue to manage through a turbulent and constantly evolving industry, we are committed to execute against our strategy with more diversified revenue sources and profit streams, all backed by strong product development engines in both generics and specialty.”
